Core Scientific price target lowered to $20 from $26 at Compass Point

Compass Point analyst Joe Flynn lowered the firm’s price target on Core Scientific (CORZ) to $20 from $26 and keeps a Buy rating on the shares as the firm updated its valuation ahead of Q4 results. Amid a number of concerns that have been impacting Core Scientific valuations, including with Microsoft (MSFT) capex and CoreWeave credit risk, the firm says it believes that the selloff below $10 provides a “significant buying opportunity” with CoreWeave’s signed 500MW contracts trading at considerable discounts. Most of the news “currently being sensationalized by media/investors similar to DeepSeek is not new,” says the analyst, who believes CoreWeave’s positioning and Core’s outlook remains “quite strong.”